ArticleLeukemia2019
CXCR5
Abstract read
In one paragraph
Article in Leukemia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Molecular Biomarkers in Prediction of High-Grade Transformation and Outcome in Patients with Follicular Lymphoma: A Comprehensive Systemic Review.International journal of molecular sciences · 2024Pooled it
- Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II study.Signal transduction and targeted therapy · 2025Trial
- C-X-C chemokine receptor type 5World journal of gastroenterology · 2025Trial
- CRISPRa screen unveils noncanonical NF-κB to boost the antitumor activity of TCR-based CAR-T cells.Cellular & molecular immunology · 2026Article
- A Versatile Anti-CXCR5 Monoclonal Antibody (CxCurrent issues in molecular biology · 2026Article
- CXCL13-CXCR5 signaling in CD8Cancer immunology, immunotherapy : CII · 2026Article
- Jump-starting the T cell response in established tumors.bioRxiv : the preprint server for biology · 2026Article
- Plasmatic CXCL13 as a biomarker of primary resistance to immunotherapy and impaired peripheral immunity in non-small cell lung cancer.Biomarker research · 2026Article
- CXCL13-CXCR5 Signaling in CD8bioRxiv : the preprint server for biology · 2026Article
- Article
- PD-1 antibody-bound progenitor-exhausted CD8Nature communications · 2026Article
- FKBP5 isoforms shape immune pathways related to tumor tolerance.Cell death discovery · 2026Article
- CXCR5 identifies stem-like resident memory CD8⁺ T cells enriched for latent EBV specificity in tonsils.Science advances · 2026Article
- The Influence of Sleep and Diet on Human Peripheral Immunity and Chronic Health Conditions.Research (Washington, D.C.) · 2026Article
- Comprehensive immune profiling of human peripheral blood mononuclear cells using two complementary spectral flow cytometry panels encompassing 60 unique markers.Frontiers in immunology · 2026Article
- Transcriptional dynamics of CD8Molecular cancer · 2025Article
- Pan-cancer single cell transcriptomic clustering reveals heterogeneous CD8Oncoimmunology · 2025Article
- Chromatin repression by PRC2 results in reduced gene expression driving key features of CD8 T cell exhaustion.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Follicular CD8+ T cells in Trypanosoma cruzi infection: helpers or killers depending on the target B cell population.PLoS pathogens · 2025Article
- The role of CD40L-expressing CXCR5Immunologic research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 3 institutions in 2 countries.
Fuliang ChuDepartment of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Haiyan S LiDepartment of Immunology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-5069-9735
Xindong LiuDepartment of Immunology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Jingjing CaoDepartment of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Wencai MaDepartment of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Ying MaDepartment of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Jinsheng WengDepartment of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Zheng ZhuInstitute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, 400038, Chongqing, China.
Xiaoyun ChengDepartment of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Zhiqiang WangDepartment of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Jingwei LiuDepartment of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Zi Yang JiangDepartment of Otorhinolaryngology-Head and Neck Surgery, The University of Texas Health Science Center of Houston, Houston, TX, USA.
Amber U LuongDepartment of Otorhinolaryngology-Head and Neck Surgery, The University of Texas Health Science Center of Houston, Houston, TX, USA.
Weiyi PengDepartment of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Jing WangDepartment of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Kumudha BalakrishnanDepartment of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Cassian YeeDepartment of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Chen DongDepartment of Immunology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Richard Eric DavisDepartment of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Stephanie S WatowichDepartment of Immunology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
Sattva S NeelapuDepartment of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA. SNeelapu@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USThe University of Texas Health Science Center · USArmy Medical University · CN
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MRegulation and function of nonlymphoid organ CD103 dendritic cellsR01AI109294 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WATOWICH, STEPHANIE S · 2015 to 2019
$2.0MSuper-Resolution OMX MicroscropeS10RR029552 · NCRR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ZAL, TOMASZ · 2011 to 2011
$1.0MRegulation and function of nonlymphoid organ CD103+ dendritic cellsR56AI109294 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WATOWICH, STEPHANIE S · 2021 to 2021
$481kNCI NIH HHS P30 CA016672NCRR NIH HHS S10 RR029552NIAID NIH HHS R01 AI109294NIAID NIH HHS R56 AI109294
Abstract
CXCR5 mediates homing of both B and follicular helper T (T
Indexed as
Adoptive TransferAnimalsB-LymphocytesCD8-Positive T-LymphocytesCell DifferentiationCoculture TechniquesFemaleGerminal CenterHumansLeukocytes, MononuclearLymphocyte ActivationLymphoma, FollicularMaleMiceMice, KnockoutMice, TransgenicCXCR5 protein, humanReceptors, Antigen, T-CellReceptors, CXCR5Transforming Growth Factor beta
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.